RE:RE:Everyone is losing money On top of that Carpha,
WELL's EBITDA is growing at a much higher rate than some of these comparables.
As revenue continues to climb, EBITDA follows and as the company scales its operations, EBITDA margins should swell up.
WELL may be trading at 11x runrate EBITDA, but on a forward next twelve months basis, it may be trading closer to only 7x EBITDA. If EBITDA multiples matter, which to banks lending WELL money, it does, it should be approaching $200MM run rate by end of 2022.
On top of significant, positive and growing EBITDA, the company has substantial free cash flows.
I think from a management reporting/updating perspective, they will no longer be releasing individual news releases for each transaction that is no "material". So if CRH picks up a few clinics or makes a small investment, those updates may be included as a sub-point in a larger news release. WELL's size is now beyond the point where small tuck-ins are material and in need of indvidual announcing. From here on, it will be important, material corporate updates, with small or tuck-in acquisitions "tucked" into the news release.